Steeve DemoProfile

Oncology — Baylor Scott & White Health, United States

LeadR Profile

Steeve DemoProfile Baylor Scott & White Health United States
6 992 ScienceLeadR Reputation 6992
Network Map

Oncology

Subspecialties: Public Health - Therapeutics - Surgery

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1995 - 2023

Source: PubMed

Mayo Clinic

could not re-read experiences after save", error); return null; } if (persistedEntries === null) { return null; } if (persistedEntries.length === 0 && sent.some((entry) => entry.isvisible !== false)) { console.warn(" re-read after save came back empty, keeping the edited entries"); return null; } this.state.current.experience = persistedEntries; const expected = this.yearsSignature(sent); const received = this.yearsSignature(persistedEntries.map((entry) => ({ isvisible: entry.isvisible, topresent: entry.topresent, year_start: entry.startperiod, year_stop: entry.endperiod }))); if (expected !== received) { console.error(" saved experiences were not persisted as sent", { sent: expected, received: received }); return false; } return true; }, async fetchExperiences() { const response = await $.ajax({ url: ajaxLoadUserData, type: "POST", data: { security: ajaxDataLoadUserData.security, data_to_load: "OrganizationHisto", } }); const parsedData = JSON.parse(response); if (parsedData.loaded === false || !parsedData.user_data || !Array.isArray(parsedData.user_data)) { return null; } return parsedData.user_data.map((value, index) => ({ company: value["name"], url: "", position: (value.hasOwnProperty("position") ? ( value["position"] ) : ( "" ) ), startperiod: value["year_start"], endperiod: value["year_stop"], topresent: (value.hasOwnProperty("topresent") ? ( value["topresent"] ) : ( false ) ), orgid: value["orgid"], isvisible: (value.hasOwnProperty("isvisible") ? ( value["isvisible"] ) : ( true ) ), description: "", tags: [], isOpen: false, ismain: (value.hasOwnProperty("ismain") ? ( value["ismain"] ) : ( (index === 0) ? true : false ) ) })); }, async loadDataOnMount() { this.loading = true; try { const experiences = await this.fetchExperiences(); this.loadFailed = experiences === null; if (experiences !== null) { this.state.current.experience = experiences; } } catch (error) { console.warn(" could not load experiences", error); this.loadFailed = true; } this.loading = false; } }, computed: { experience: { get() { return this.state.current.experience }, }, }, async mounted() { await this.loadDataOnMount() }, } }; })

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 920

Citations

Citations: 24 536 1st author: 90 Last author: 172 Unique author: 33


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Efficacy and Safety of Adjuvant Radiotherapy in Re-excised Soft-tissue Sarcoma After Unplanned Resection.
sarcoma, neoplasms, safety, multivariate analysis, tissues, radiotherapy, adjuvant
Oncologist20235
Radioligand therapies in cancer: mapping the educational landscape in Europe.
education, teaching, nuclear medicine, universities, therapeutics, neoplasms
Eur J Nucl Med Mol Imaging20234
Why will there never be a randomized trial for NTRK-rearranged tumors?
neoplasms
Ann Oncol Top journal20238
[Endometrial stromal sarcoma: French Guidelines from the French Sarcoma Group and the Rare Malignant Gynecologic Tumors Group].
neoplasms, morcellation, sarcoma, sarcoma, endometrial stromal, therapeutics
Bull Cancer20231
Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial.
glioma, safety, molecular biology, neoplasms, thyroid carcinoma, anaplastic, therapeutics
Nat Med Top journal2023160

Clinical Studies 103

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 31 Study Chair: 3 Sub-Investigator: 3

By phase:

Phase 2 47
Phase 3 23
N/A 16
Phase 1 10
Phase 1/Phase 2 5
Phase 2/Phase 3 1

By status:

Completed 54
Recruiting 31
Active, not recruiting 11
Terminated 3
Unknown status 2
Suspended 1

By type:

By Monocentric/Multicentric:

monocentric 14
multicentric2to4 7
multicentric5to9 18
multicentricup10 63

Main Topics

Ongoing Clinical Trials

5 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
HDM201 and Pazopanib in Patients With P53 Wild type Advanced Metastatic Soft Tissue Sarcomas
NCT05180695 — safety, pharmaceutical preparations, disease progression, sarcoma, genes, p53, response evaluation criteria in solid tumors, tissues
Phase 1/Phase 2Active not recruiting2022
Study of Vimseltinib for Tenosynovial Giant Cell Tumor
NCT05059262 — cells, genes, dcc, safety, giant cell tumors, giant cell tumor of tendon sheath, neoplasms, double-blind method, tendons, giant cells, synovitis, pigmented villonodular, therapeutics, synovitis
Phase 3Active not recruiting2021
Efficiency of Imatinib Treatment After 10 Years of Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (Gist Ten)
NCT05009927 — mesylates, gastrointestinal stromal tumors, neoplasms, tablets, maintenance, protein-tyrosine kinases, tyrosine, therapeutics, imatinib mesylate, mutation
Phase 2Recruiting2022
Study of INBRX 109 in Conventional Chondrosarcoma
NCT04950075 — cells, chondrosarcoma, apoptosis, cell death
Phase 2Active not recruiting2021
Real Word European Registry of NTRK Fusions and Other Rare Actionable Fusions (TRacKING)
NCT04921553 — registries, genes, quality of life, data collection, proto-oncogene proteins c-sis, neoplasms, gene rearrangement, gene fusion, therapeutics, mutation
N/ARecruiting2021

LeadR Networks

Main global connection map